Brokerages Set GeneDx Holdings Corp. (NASDAQ:WGS) Target Price at $87.43

Shares of GeneDx Holdings Corp. (NASDAQ:WGS) have been assigned a consensus rating of “Moderate Buy” from the eight ratings firms that are covering the stock, MarketBeat reports. Two research analysts have rated the stock with a sell recommendation and six have given a buy recommendation to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $87.4286.

WGS has been the subject of several analyst reports. BTIG Research cut their price target on GeneDx from $170.00 to $90.00 and set a “buy” rating for the company in a research note on Tuesday, May 5th. Wall Street Zen lowered shares of GeneDx from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Craig Hallum restated a “buy” rating and set a $85.00 price objective on shares of GeneDx in a research report on Tuesday, May 5th. Weiss Ratings downgraded shares of GeneDx from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, June 1st. Finally, Zacks Research cut shares of GeneDx from a “hold” rating to a “strong sell” rating in a research note on Monday, June 29th.

Insider Activity

In other GeneDx news, Director Keith A. Meister acquired 533,758 shares of the stock in a transaction on Thursday, May 7th. The shares were bought at an average price of $37.86 per share, with a total value of $20,208,077.88. Following the acquisition, the director owned 3,761,908 shares of the company’s stock, valued at $142,425,836.88. This trade represents a 16.53% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Casdin Capital, Llc bought 185,000 shares of the business’s stock in a transaction dated Tuesday, May 19th. The shares were acquired at an average cost of $42.60 per share, with a total value of $7,881,000.00. Following the completion of the purchase, the director owned 3,367,164 shares in the company, valued at approximately $143,441,186.40. This represents a 5.81% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last three months, insiders have purchased 2,256,420 shares of company stock valued at $93,144,340 and have sold 21,699 shares valued at $1,295,646. Corporate insiders own 25.17% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Westfield Capital Management Co. LP boosted its position in shares of GeneDx by 87.1% during the 4th quarter. Westfield Capital Management Co. LP now owns 1,018,261 shares of the company’s stock worth $132,435,000 after purchasing an additional 474,167 shares in the last quarter. ARK Investment Management LLC acquired a new stake in shares of GeneDx in the third quarter valued at about $48,157,000. Franklin Resources Inc. lifted its stake in shares of GeneDx by 60.4% in the fourth quarter. Franklin Resources Inc. now owns 1,092,988 shares of the company’s stock valued at $142,154,000 after purchasing an additional 411,607 shares during the period. Invesco Ltd. boosted its holdings in GeneDx by 59.2% during the fourth quarter. Invesco Ltd. now owns 786,466 shares of the company’s stock worth $102,288,000 after buying an additional 292,394 shares in the last quarter. Finally, Amova Asset Management Americas Inc. purchased a new stake in GeneDx during the third quarter worth about $31,444,000. Hedge funds and other institutional investors own 61.72% of the company’s stock.

Key Headlines Impacting GeneDx

Here are the key news stories impacting GeneDx this week:

• Neutral Sentiment: Multiple law firms, including Rosen, Robbins LLP, Bronstein Gewirtz & Grossman, Faruqi & Faruqi, Kessler Topaz, The Schall Law Firm, Bernstein Liebhard, Robbins Geller, and Kahn Swick & Foti, issued reminders about an August 3, 2026 deadline for investors to seek lead-plaintiff status in the GeneDx securities class action. Article link
• Neutral Sentiment: The lawsuits allege GeneDx misled investors about the acquisition’s performance and potential synergies, with the litigation centered on purchases made between April 16, 2025 and May 4, 2026. Article link
• Negative Sentiment: The legal actions reference a sharp 49% stock drop on May 5, 2026 after GeneDx’s Q1 results, including a $31.2 million impairment charge, reinforcing concerns about execution and acquisition-related write-downs. Article link
• Negative Sentiment: Bronstein Gewirtz & Grossman and other firms announced or highlighted class action filings against GeneDx and certain executives, adding to the headline risk and potential overhang on the shares. Article link

GeneDx Stock Performance

NASDAQ WGS opened at $69.39 on Friday. The firm has a market cap of $2.06 billion, a P/E ratio of -25.89 and a beta of 1.90. GeneDx has a 52-week low of $32.21 and a 52-week high of $170.87. The business’s 50-day moving average price is $54.42 and its 200 day moving average price is $77.47. The company has a quick ratio of 2.95, a current ratio of 3.09 and a debt-to-equity ratio of 0.38.

GeneDx (NASDAQ:WGS) last posted its quarterly earnings data on Monday, May 4th. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.22). GeneDx had a negative net margin of 17.58% and a positive return on equity of 9.15%. The company had revenue of $102.25 million for the quarter, compared to analysts’ expectations of $112.46 million. During the same period in the prior year, the company earned ($0.23) earnings per share. On average, equities research analysts expect that GeneDx will post -1 earnings per share for the current year.

About GeneDx

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.